This Web Site is committed to the memory of Janis Morrow.
Videos
Videos Best Viewed With Internet Explorer
On-Demand Video of Live Press
Conference Coverage at
Digestive Disease Week 2009
AASLD: Nov 10-09 (Liver Meeting)
Once-Daily HCV Protease Inhibitors Show Early Promise
AASLD: New Drug Boosts HCV Clearance
Two new drugs"Telaprevir and Boceprevir" Sep 09
AASLD Nov 09: New Strategies in Liver Cancer and Hepatitis B- Nov 09
Teenager Jazzy was born with hepatitis C Aug 09
Members Of Our Forum Winning The Battle Against HCV
Current and Future Treatment of Chronic Hepatitis C July 09
Hepatitis C Virus and Hepatocellular Carcinoma May 09
Head To Head Study peginterferon alfa-2a (Pegasys) verses peginterferon alfa-2b (Pegintron) both in combination with ribavirin July 09
Treatment of Hepatitis C Genotype 1 Infected Patients Sep 01 09
Dr. Galati Discussed Hepatitis C Updates Aug 09
2009 Annual Meeting of the European Association for the Study of the Liver
Metabolic Syndrome Hikes Mortality in Hepatitis C
2008/AASLD: Hepatologists Eye Protease Inhibitors for Hepatitis C
2008/Investigational Agents for Viral Hepatitis
From The Liver Meeting 08/ Approved HCV Agents
Liver Cancer/Treating/Diagnosing/Symptoms
Experimental Treatment Liver Cancer
AASLD New Strategies in Liver Cancer
Management of Hepatitis C in the Pre-Transplant Patient
From The American Liver Foundation
6th Update - Video "Liver Cancer"
Tests
A new type of MRI of the liver developed at Mayo Clinic called MRE can reduce the need for liver biopsy in some patients with liver disease. Dr. Jayant Talwalkar, a hepatologist from the Mayo Clinic, discusses the types of patients that may benefit from this scan and how it may decrease the need for liver biopsy.
Magnetic resonance elastography (MRE)
Band Ligation of Esophageal Varicies 2009
News/2009 Videos
Hepatitis C Exposure Rose Medical Center
FDA panel backs cut in maximum Tylenol dosage July 09
Veterans face risk of disease exposure June 09
Man Living With Hepatitis C Tells Medical Marijuana Story
Full Story: VA: 3 patients HIV-positive after clinic mistakes
Positive Hepatitis Results Denied By VA
News Rewind (General Medical Updates)
General practitioners Can't Spot Hepatitis C in UK
Presented By : HCV Advocate
On-Demand Video of Live Press Conference
Coverage at
Digestive Disease Week 2009
Liver Disease: Compliance, Awareness, and Testing
Click The Link Below To View Video Please
http://www.medpagetoday.com/tbindex.cfm?tbid=14363
Sexual Transmission Among Heterosexual Monogamous Couples
Oct 17 09
AASLD: Once-Daily HCV Protease Inhibitors Show Early PromiseNarlaprevir (formerly called SCH 900518 |
||
|
Nov 10
At least 85% of patients adding narlaprevir (formerly called SCH 900518) to pegylated interferon-alfa-2b (PEGIntron) and ribavirin (Rebetol) after four weeks achieved rapid virological responses, compared with no patients receiving only interferon and ribavirin, according John Vierling, MD, of Baylor College of Medicine in Houston...... Continue Reading
AASLD:
AASLD: New Drug Boosts HCV Clearance
Boceprevir is one of two HCV protease inhibitors in late-stage development, the other being telaprevir
|
||
BOSTON -- Most hepatitis C patients
who are initially unresponsive to standard therapy
were able to achieve sustained virologic responses
when the investigational drug boceprevir was added,
a researcher reported here.
Sustained responses were seen in 55% of patients receiving 44 weeks of boceprevir after showing no virologic response to four weeks of pegylated interferon-alfa-2b (PEGIntron) and ribavirin (Rebetol) in a Phase II trial, said Paul Kwo, MD, of Indiana University in Indianapolis. Kwo, speaking here at the American Association for the Study of Liver Disease meeting, was reporting on two secondary analyses of data from the SPRINT-1 trial of boceprevir, an inhibitor of the hepatitis C virus (HCV) NS3 protease enzyme. He had presented the main findings of the 520-patient study earlier this year at the European Association for the Study of the Liver meeting in Copenhagen. (See Sustained Response Seen with New Hepatitis C Drug)
|
October 30-November 3, 2009 Boston, Massachusetts
Nov 10
Added Anti-Viral Halves Duration of Hepatitis C Treatment
Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, lead drug candidate, is an oral hepatitis C protease inhibitor and one of the advanced of a new class of antiviral treatments in clinical development that target hepatitis C virus (HCV), infection.
Hope for Hepatitis C patients: Two new drugs
"Telaprevir and Boceprevir"
AASLD Nov 09: New Strategies in Liver Cancer and Hepatitis B
Teenager Jazzy was born with hepatitis C
Her Story
Follow Carolyn's Story On Our Message Boards
74gibson aka Carolyn stage 1 grade 2/Geno 1 First Shot March 30th GO Carolyn /Four Week PCR soon/Feelingthe deep bone aches. Apr 22nd Four week check up, shortness of breath is getting better 39721.1 Waiting to see if our girlfriend has a two log drop ((( Carolyn)))40046.1 Sep 4 labs 40881.1
Update July 2 CAROLYN IS UD>>>AT 12 wk PCR 40361.1 Getting on the right rescue drug Oct 15 41226.1 April 09 Feeling Great After Treatment 42453.1
YES YES YES SHE DID IT >>> SVR 43403.1
Alan's Story
Follow Alan On Our Message Boards
coasterad AKA Alan/Sailor Finished Treatment. Four Weeks after Treatment 39764.1
YES............ ALL CLEAR............ May 9 39896.1
READ Alans sort of Diary 40055.1 Alan IS SVR Alan's Thread is here 41315.1
Current and Future Treatment of Chronic Hepatitis C July 09
Hepatitis C Virus and Hepatocellular Carcinoma
Head-to-Head Trial Finds HCV Regimens Equalpeginterferon alfa-2a (Pegasys) verses peginterferon alfa-2b (Pegintron) both in combination with ribavirin |
By Crystal
Phend, Staff Writer, MedPage Today
Published: July 22, 2009
Reviewed by Dori
F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical
School, Boston and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
Dr. Galati Discussed Hepatitis C Updates
2009 Annual Meeting of the European Association for the Study of the Liver*
April 22-26, 2009 | Copenhagen, Denmark
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
http://www.clinicaloptions.com
Metabolic Syndrome Hikes Mortality in Hepatitis C
By John Gever,
Senior Editor, MedPage Today
Hepatitis C study shows early treatment works
AASLD: Hepatologists Eye Protease Inhibitors for Hepatitis C
|
|
Liver Cancer/Treating/Diagnosing/Symptoms
Experimental Treatment Liver Cancer
Nov 2008
AASLD New Strategies in Liver Cancer
Liver Transplantation/Living Donation/Standard Risk/ High Donor Risk
How to use the Video Wall: To find out what each video is
about hover your mouse pointer over the video preview you want to
find out more about. After about a second, information about that
video will appear below it. To watch a video story, click the
preview to be taken to the viewing page for that particular video.
http://www.transplantcafe.com/group/news
Management of Hepatitis C in the Pre-Transplant Patient
New MRI Technique Reduces Need For Liver Biopsy
http://www.videomd.com/featured_video_category.aspx?cid=27
Magnetic resonance elastography (MRE)
Band Ligation of Esophageal Varicies
Veterans face risk of disease exposure
Man Living With Hepatitis C Tells Medical Marijuana Story
Full Story: VA: 3 patients HIV-positive after clinic mistakes
Positive Hepatitis Results Denied By VA
News Rewind (General Medical Updates)
Salmonella
'Am I Number 12?
Support: Janis and Friends
Presented By : HCV Advocate
HCV Game/Quiz
